IntegriChain names Chris Hare chief revenue officer for 2027 expansion

IntegriChain appointed Chris Hare as chief revenue officer as the revenue-optimization company marks 20 years and prepares for further expansion in 2027.

Hare will oversee commercial strategy, expand customer relationships, improve revenue operations and support adoption of the company’s ICyte platform. That remit fits a business selling technology, data analytics, consulting and managed services to pharmaceutical manufacturers throughout the commercialization lifecycle.

What will Hare be expected to change?

Hare’s priorities are clearer revenue forecasting, stronger sales operations, a more integrated commercial strategy and deeper customer engagement.

He has more than 20 years of experience building and managing revenue organizations across pharmaceutical commercialization, healthcare technology and software-as-a-service businesses. His background spans both manufacturer and software settings, useful for serving drugmakers at different launch stages.

The announcement sets no revenue, customer, hiring or ICyte-adoption targets. It also gives no sales-team size or coverage model. Claims about his expected contribution therefore remain directional rather than measurable.

What does his record show?

Hare joins IntegriChain from Intelerad, where he served as chief growth and revenue officer and led a global commercial organization. The announcement says that team achieved double-digit annual growth, contributing to expansion before GE HealthCare acquired the company earlier in 2026.

The growth claim gives no revenue base, period, segment or calculation. It is an employer-reported result, not a standalone benchmark.

Hare managed commercial operations at the private-equity-backed healthcare technology business, covering revenue growth, organizational development and strategic execution.

Before Intelerad, he held senior commercial leadership roles at several healthcare technology companies, including Net Health. There, he led sales for a specialty software portfolio involving electronic medical records, revenue-cycle management and predictive analytics, and supported multiple product-line introductions.

That experience commercializing data-driven tools across healthcare markets aligns with IntegriChain’s plan to combine software, analytics and professional services in one platform.

Who does IntegriChain need to sell to?

IntegriChain provides technology, data analytics, consulting and managed services to help pharmaceutical manufacturers manage drug pricing, reimbursement, market access and revenue management throughout the commercialization lifecycle. Hare’s customer remit will span emerging biopharma companies preparing for initial launches and large established pharmaceutical businesses.

“For 20 years, IntegriChain has helped biopharma manufacturers turn commercialization complexity into clarity, and we’re entering our next chapter with real momentum,” CEO Josh Halpern said.

Halpern cited Hare’s pharmaceutical sales background and record building scalable commercial organizations. Hare began at Salix Pharmaceuticals in sales and commercial leadership, gaining direct exposure to market access, pricing, reimbursement and commercial execution.

Hare said: “I couldn’t be more excited to join IntegriChain. What drew me here was the strength of the business, the momentum of this team, and most importantly, the people and culture behind it.”

The quotations supply conviction, not evidence of a new sales motion. The measurable brief remains customer growth, platform adoption and tighter operating discipline.

How does ICyte fit the strategy?

ICyte integrates technology, data, consulting and managed services for pharmaceutical commercialization. The company says it connects commercial, financial and operational workflows, replacing fragmented processes with integrated analytics and management tools.

Its stated use cases cover patient access, net revenue performance, compliance and revenue leakage. The goal is to show manufacturers which financial and operational factors affect product commercialization, but the announcement gives no customer outcomes or performance data.

Regulatory and reimbursement changes add pressure on pricing, contracting, reimbursement and revenue management. The announcement cites Inflation Reduction Act provisions and changes affecting the federal 340B Drug Pricing Program, increasing the need for accurate data and coordinated financial processes.

Those pressures create demand for tools that connect those functions across organizations. IntegriChain’s opportunity is to become a broader technology-and-services partner while improving visibility into product performance and profitability.

That is a claim about market need, not a forecast. The announcement gives no market size, win rate, sales-cycle time or adoption figure.

What does the ownership structure change?

Nordic Capital backs IntegriChain. The private-equity investor focuses on healthcare and technology, aligning with the company’s market and Hare’s background.

Hare has worked with investor-backed businesses and advised companies backed by angel investors, venture-capital firms and private-equity sponsors. He also has acquisition-diligence and integration experience, potentially relevant as IntegriChain develops its platform and market presence.

His work has included managing growth expectations, improving commercial execution and developing scalable business processes. The announcement reports no financial targets, deal terms or performance incentives for his appointment.

Where does the expansion go?

As IntegriChain enters its third decade, Hare will strengthen existing customer relationships, broaden ICyte adoption, develop customer partnerships and build more structured commercial operations. He will also extend the company’s reach across biopharma and support continued platform development.

Hare brings experience scaling healthcare software businesses and managing complex enterprise sales organizations. His prior work includes building revenue-operations teams, implementing sales-technology infrastructure, and establishing reporting and forecasting processes for consistent performance.

These are operating changes, not announced product releases. The first test is whether commercial execution turns a broad product-and-services portfolio into measurable adoption. That result will matter more than the appointment’s celebratory wording.